News for BeiGene, Ltd. (6160.HK)

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cel…

PR NewswireTHOUSAND OAKS, Calif., March 4, 2025 THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U

ImmunityBio Inc (IBRX), a prominent immunotherapy company, has released its financial results for the fourth quarter and full year ending December 31, 2024. The

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where BeiGene, Ltd.

PR NewswireTHOUSAND OAKS, Calif., March 1, 2025 Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

BeiGene's (BeOne Medicines) Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively. Check out why I rate ONC stock as a Buy.

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O N688235.SS - Beigene LtdQ4 2024 Beigene Ltd Earnings PresentationFeb 27, 2025 / 01:00PM GMT ===

BeiGene Ltd's robust revenue growth and reduced operating loss highlight its financial resilience and commercial success.The company's focus on oncology therap

BeiGene, Ltd. (NASDAQ:ONC) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ETCompany ParticipantsDan Maller - Head, Investor RelationsJohn Oyler...

BeiGene Ltd (ONC), a prominent global oncology company, has released its financial results and corporate updates for the fourth quarter and full year 2024. The

[url="]BeiGene[/url], Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today an

Revenue: Achieved $1.1 billion in Q4 2024, surpassing the estimated $1.047 billion, marking a 78% increase year-over-year.Annual Revenue: Reached $3.8 billion

Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss an…

**media[550677]**

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline o…

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. ( ZYME) a clinical-stage biotechnology company developing a diverse pipeline of

BeiGene Ltd (ONC), a prominent global oncology company, has announced its participation in two upcoming investor conferences. The company, which plans to rebran